Monitor for additional tranches of the offering and further debt settlements, which could increase dilution. Assess whether the capital raised meaningfully advances the company's drug development programs, particularly Lucid-MS.
Price Chart
Executive Summary
Quantum BioPharma has closed the first tranche of its offering, raising $3.75 million through the issuance of 3,750 Debenture Units, with a director participating for $300,000. The company also completed a debt settlement by issuing 370,457 Class B shares to settle $1.12 million in debt, including obligations to insiders. Both transactions are related-party dealings exempt from formal valuation and shareholder approval under MI 61-101.
Key Financial Metrics
Key Facts
- Quantum BioPharma raised $3,750,000 in the first tranche of its offering through 3,750 Debenture Units.
- A director participated in the offering, subscribing for $300,000 worth of Debenture Units, constituting a related-party transaction.
- The company settled $1,117,727 in debt by issuing 370,457 Class B subordinate voting shares to creditors, including insiders.
- Both the offering and debt settlement are exempt from minority shareholder approval under MI 61-101 due to size relative to market cap.
- Proceeds will be used for business development and general working capital purposes.
Financial Impact
$3.75 million raised in debt financing; $1.12 million in debt eliminated via share issuance
Risk Factors
- Dilution risk from future share issuances in additional tranches or debt settlements.
- Related-party transactions may raise governance concerns among minority shareholders.
- Low market cap ($9M) increases sensitivity to dilution and potential stock volatility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259989 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 19d ago | 6-K | $3.11 | awaiting T+20 | — | $2.32 (−25.40%) |
Oct 6, 2026 21d ago | 6-K | $3.09 | awaiting T+20 | — | $2.32 (−24.92%) |
Oct 6, 2026 21d ago | Press Release | $3.09 | awaiting T+20 | — | $2.32 (−24.92%) |
Oct 5, 2026 22d ago | SC 13G/A | $3.27 | awaiting T+20 | — | $2.32 (−29.05%) |
Sep 24, 2026 4w ago | 6-K | $4.00 $2.27 | ▼ −43.25% | ▼ −42.83% | $2.32 (−42.00%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.32 (−37.63%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.32 (−37.63%) |
Sep 15, 2026 6w ago | 6-K | $3.46 $2.89 | ▼ −16.47% | ▼ −19.45% | $2.32 (−32.95%) |
Sep 1, 2026 7w ago | 6-K | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.32 (−24.68%) |
Sep 1, 2026 7w ago | Press Release | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.32 (−24.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers